Back to News
Nov 11, 2025 12:00 PM

These Analysts Revise Their Forecasts On Wave Life Sciences Following Q3 Results

Wave Life Sciences Ltd (NASDAQ:WVE) reported worse-than-expected third-quarter financial results on Monday.

WAVE Life Sciences reported quarterly losses of 32 cents per share which missed the analyst consensus estimate of losses of 30 cents per share. The company reported quarterly sales of $7.608 million which missed the analyst consensus estimate of $11.130 million.

“In the third quarter, we achieved key clinical objectives with WVE-007 for obesity and WVE-006 for alpha-1 antitrypsin deficiency, which validate the impact of our proprietary chemistry and further solidify our growing leadership in RNAi and RNA editing,” said Paul Bolno, MD, MBA, President and Chief Executive Officer at Wave Life Sciences. “Coming out of ObesityWeek®, it ...